Share
Congressional briefing organized by the Deadliest Cancers Coalition with the Congressional Caucus on Deadliest Cancers, Thursday, June 19, 2014, Washington, DC
Recent projections for the top cancer killers in 2030 confirmed some encouraging trends but also sounded a warning bell. Continue reading
Share
A recent analysis of studies that looked at the benefits of screening concluded that the evidence remains insufficient to make a strong case for or against screening. The authors of an accompanying editorial did note, however, that screening has a much greater potential to be beneficial in the highest-risk patients, and it is appropriate to allow clinicians caring for these patients to continue to offer screening. Clearly, more data are needed.
Although current liver cancer screening methods are not perfect, the Hepatitis B Foundation encourages liver cancer screening. Early detection can give patients more treatment options, and potentially a greater chance of successful treatment. Screening does save lives.
Roxanne Nelson, Medscape, June 19, 2014, reports on study published online June 16 in the Annals of Internal Medicine.
When looking at the effects of screening on mortality, 2 clinical trials and 18 observational studies provided very-low-strength evidence from which to draw conclusions about the mortality effects of HCC screening, as compared with no screening.
Both of the trials were conducted in China in areas with high HCC prevalence, and most participants had hepatitis B with or without cirrhosis. One of the trials (n = 9757) offered serum α-fetoprotein testing and ultrasonography every 6 months, and participants in the control group (n = 9443) were not made aware of the study or actively followed. HCC mortality was less frequent in the screened group (83.2 vs 131.5 per 100,000 person-years; rate ratio, 0.63).
Read article in its entirety here.
Posted in Uncategorized
Share
Liver cancer is the world’s second leading cause of cancer deaths, according to the latest World Cancer Report 2014 released by the International Agency for Research on Cancer (IARC), which is the specialized cancer agency of the World Health Organization (WHO). About 800,000 deaths per year are related to liver cancer. Continue reading
Posted in Deadliest Cancers, General Hep B info, HBV Prevention, Hep B Prevention, Hep B Treatment, hepatocellular carcinoma, Liver cancer, Liver Cancer Awareness, liver cancer prevention, Research, Uncategorized, Vaccines, Viral Hepatitis
Tagged Cancer deaths, chronic HBV, Early detection, Hepatitis B, Hepatitis B Foundation, hepatitis B vaccine, hepatocellular carcinoma, liver cancer, viral hepatitis, World Cancer Report, World Health Organization
Share
HBF is pleased to connect our blog readers to Christine Kukka’s monthly HBV Journal Review that she writes for the HBV Advocate. The journal presents the
latest in hepatitis B research, treatment, and prevention from recent academic and medical journals. This month, the following topics are explored:
Posted in Uncategorized
Share
In recognition of Rare Diseases Day today, Liver Cancer Connect is honored to feature an article by guest blogger, Gail Trecosta. Gail’s son is fighting a rare form of liver cancer.
We’ve all heard or seen heartbreaking stories of children with cancer. Ours began in October 2012. Our world turned upside down when our 13-year-old son was diagnosed with fibrolamellar hepatocellular carcinoma (FHC).
Posted in Advocacy, Chemotherapy, Deadliest Cancers, Fibrolamellar cancer, hepatocellular carcinoma, Liver Cancer Awareness, liver cancer prevention, Liver resection surgery, Public Health, Radiation therapy, Rare Diseases Day, Research, Sequestration, Uncategorized
Tagged Cancer research, deadliest cancers, Fibrolamellar Cancer Foundation, Fibrolamellar carcinoma, hepatocellular carcinoma, liver cancer, National Institutes of Health, Rare Diseases Day, Sequestration